The strong revenue acceleration and solid 2026 guidance suggest improving momentum. The CFO transition is routine corporate governance. Traders should monitor whether the company can achieve its 2026 guidance range, particularly given the $7.5M Medicare LCD headwind mentioned.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $18.46entry
- T+1 · 9mo ago +1.95%α +2.50% · $18.82
- T+5 · 9mo ago +3.25%α +4.35% · $19.06
- T+20 · 8mo ago −2.06%α +3.18% · $18.08
- T+60 · 6mo ago +14.57%α +7.62% · $21.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CareDx reported strong Q4 and full-year 2025 financial results with 25% YoY revenue growth in Q4 and 14% for the full year. The company issued 2026 revenue guidance of $420M-$444M and announced CFO transition, with Keith Kennedy appointed as new CFO following Nathan Smith's resignation. Despite GAAP net losses, non-GAAP profitability improved and cash flow remained strong.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $108M (+25% YoY), Full-year 2025 revenue: $380M (+14% YoY)
- GAAP net loss: $4M in Q4 2025 vs. $88M net income in Q4 2024 (due to $96M litigation reversal in 2024)
- Non-GAAP net income: $6M in Q4 2025, $32M for full-year 2025
- 2026 revenue guidance: $420M-$444M, Adjusted EBITDA: $30M-$45M
- CFO transition: Keith Kennedy appointed, Nathan Smith resigned
- Strong cash flow: $21.4M from operations in Q4, $42M for full year
Financial Impact
Revenue growth accelerating to 25% in Q4 2025 from 14% full-year growth, with 2026 guidance implying 10.5%-17.4% growth. Non-GAAP profitability maintained despite GAAP losses.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Testing services | $274.5M | +10.0% |
| Patient and digital solutions | $56.9M | +31.0% |
| Product | $48.4M | +19.0% |
Risk Factors
- GAAP net losses in 2025 ($21M) despite revenue growth
- 2026 guidance range is wide ($30M-$45M adjusted EBITDA)
- Medicare LCD expected to impact 2026 revenue by $7.5M
- CFO transition could create temporary execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001217234-26-000015 |
| Document: cdna-20260224.htm | 0001217234-26-000015 |
| Document: 0001217234-26-000015-index-headers.html | 0001217234-26-000015 |
| Document: 0001217234-26-000015-index.html | 0001217234-26-000015 |
| Document: 0001217234-26-000015.txt | 0001217234-26-000015 |
Track record
16 reports on CDNA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $77.88 Now $73.72 −5.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $77.88 Now $73.72 −5.34% settles Feb 11
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $81.17 Now $73.72 −9.18% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $80.77 Now $73.72 −8.73% settles Feb 8
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $78.56 Now $73.72 −6.16% settles Feb 4
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $87.41 Now $73.72 −15.66% settles Jan 28
- Oct 29, 202618d ago Institutional Cluster Bearish 4/10 Entry $71.52 Now $73.72 −3.08% settles Jan 27
- Aug 6, 202614w ago Insider Cluster Neutral 3/10 Entry $46.69 to $86.54 Now $73.72 +57.89% ▲ +85.34% +87.47% vs SPY
- Aug 4, 202614w ago 144 Neutral 2/10 Entry $45.50 Now $73.72 +62.02% No price data
- Jul 17, 202617w ago Insider Cluster Neutral 4/10 Entry $39.73 Now $73.72 +85.55% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers